Nexalin Technology (NXL) Net Income towards Common Stockholders Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) Net Income towards Common Stockholders Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 12.92% |
| 10 | Nexalin Technology | 6.98 Mn | 5.97 Mn | 8,897.00 | -41.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.63% |
| Mar 31, 2026 | -5.51% |
| Dec 31, 2025 | 15.98% |
| Sep 30, 2025 | 7.02% |
| Jun 30, 2025 | -23.08% |
| Mar 31, 2025 | -89.82% |
| Dec 31, 2024 | -262.33% |
| Sep 30, 2024 | -6.58% |
| Jun 30, 2024 | -56.18% |
| Mar 31, 2024 | -39.89% |
| Dec 31, 2023 | -2.91% |
| Sep 30, 2023 | -656.54% |
| Jun 30, 2023 | -82.72% |
| Mar 31, 2023 | -90.32% |
| Dec 31, 2022 | -27.30% |
| Sep 30, 2022 | 83.34% |